Nihon Kohden to take Cyberonics tech to Japan
This article was originally published in Clinica
Executive Summary
Cyberonics has signed up Nihon Kohden as the exclusive distributor of its vagus nerve stimulation (VNS) therapy systems to epilepsy patients in Japan. Houston, Texas-based Cyberonics is currently working alongside Nihon Kohden to obtain the necessary Japanese regulatory and reimbursement approvals for the technology. Nihon Kohden (Tokyo, Japan) said that the deal boosted its existing portfolio of products in the epilepsy market, such as electroencephalogram (EEG) monitoring systems. Financial details of the deal were not revealed. The FDA-approved VNS system is a non-drug option, designed to treat refractory epilepsy with the use of pulsed electrical signals to the vagus nerve. The device has also been approved for treating treatment-resistant depression. However, the firm was unable to secure financial backing for additional clinical trials that were requested by the FDA in order to evaluate the long term efficacy of the product.
You may also be interested in...
Alere aided by professional diagnostics sales in fourth quarter
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra and Stout to work on expandable interbody device
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe eyes portfolio expansion to help boost molecular diagnostics credentials
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals